SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London.
Please contact your Jefferies representative to request a one-on-one meeting with management.
About ASLAN Pharmaceutical
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat, a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com |
Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
Related news for (ASLN)
- ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
- ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
- ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
- ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients